Xu L - Search Results

1

Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6.

Xu L, Frankel P, Jackson D, Rotunda T, Boshans RL, D'Souza-Schorey C, Foster DA. Xu L, et al. Mol Cell Biol. 2003 Jan;23(2):645-54. doi: 10.1128/MCB.23.2.645-654.2003. Mol Cell Biol. 2003. PMID: 12509462 Free PMC article.

2

Phospholipase D in cell proliferation and cancer.

Foster DA, Xu L. Foster DA, et al. Among authors: xu l. Mol Cancer Res. 2003 Sep;1(11):789-800. Mol Cancer Res. 2003. PMID: 14517341 Review.

3

Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.

Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Shi M, et al. Among authors: xu l. Cancer Lett. 2007 Dec 18;258(2):268-75. doi: 10.1016/j.canlet.2007.09.003. Epub 2007 Oct 18. Cancer Lett. 2007. PMID: 17949898 Free PMC article.

4

Regulation of sprouty stability by Mnk1-dependent phosphorylation.

DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. DaSilva J, et al. Among authors: xu l. Mol Cell Biol. 2006 Mar;26(5):1898-907. doi: 10.1128/MCB.26.5.1898-1907.2006. Mol Cell Biol. 2006. PMID: 16479008 Free PMC article.

5

Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination.

Xu L, Lubkov V, Taylor LJ, Bar-Sagi D. Xu L, et al. Curr Biol. 2010 Aug 10;20(15):1372-7. doi: 10.1016/j.cub.2010.06.051. Epub 2010 Jul 22. Curr Biol. 2010. PMID: 20655225 Free PMC article.

6

Spry2 expression correlates with BRAF mutation in thyroid cancer.

Xu L, Zhou JL, Cohen M, Bar-Sagi D, Patel KN. Xu L, et al. Surgery. 2010 Dec;148(6):1282-7; discussion 1287. doi: 10.1016/j.surg.2010.09.028. Surgery. 2010. PMID: 21134562

7

Escorting Ras.

Zheng ZY, Xu L, Bar-Sagi D, Chang EC. Zheng ZY, et al. Among authors: xu l. Small GTPases. 2012 Oct-Dec;3(4):236-9. doi: 10.4161/sgtp.20460. Epub 2012 Jun 27. Small GTPases. 2012. PMID: 22735486 Free PMC article.

8

Cross-cultural adaptation of the simple Chinese version of the medication adherence reasons scale in patients undergoing adjuvant endocrine therapy for breast cancer.

Xu L, Li P, Hu Y, Xing W, Qiu J, Zhang X, Jia L, Jing F, Liu Y, Li L, Lu C. Xu L, et al. BMC Cancer. 2025 Jan 8;25(1):41. doi: 10.1186/s12885-024-13382-4. BMC Cancer. 2025. PMID: 39780104

9

Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy.

Luo Y, Nie M, Chen Y, Huang X, Cui X, Lin W, Xu L, Li E, Cheng Y. Luo Y, et al. Among authors: xu l. Curr Cancer Drug Targets. 2025 Jan 6. doi: 10.2174/0115680096327635241021115944. Online ahead of print. Curr Cancer Drug Targets. 2025. PMID: 39779573

10

Correspondence on " 'An eye for an eye' therapeutic strategy for cavernous sinus dural arteriovenous fistula" by Xu et al.

Xu L, Zheng J. Xu L, et al. J Neurointerv Surg. 2025 Jan 8:jnis-2024-022938. doi: 10.1136/jnis-2024-022938. Online ahead of print. J Neurointerv Surg. 2025. PMID: 39778932 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,894 results

Search Page

Filters